Church & Dwight Co., Inc. (NYSE: CHD) — A Best-in-Class Staple That Lost a Step, Still Priced for the Old One

Report date: 2026-06-14. Fiscal year ends December 31. All figures USD unless noted.

⚡ Claude’s Take

This is the author’s own independent opinion and general information only — not investment advice. The analysis that follows is presented without a recommendation or price target; the single opinion in this article is contained in this block.

Verdict: HOLD — a genuinely high-quality, defensive business priced richer than its current growth and returns justify. Fair-value zone ~$80–88 (≈22–24x adjusted EPS / ~15–16x EV/EBITDA — roughly where management and the buyback bought in late 2025). Not a short. At ~$97.56 it is fairly-to-fully valued; I’d accumulate on a pullback toward the low-$80s, not here.

Church & Dwight is the kind of franchise you want to own: a ~180-year-old portfolio of #1/#2 niche brands (Arm & Hammer, Trojan, OxiClean, Batiste, Hero, TheraBreath), a value-plus-premium “barbell” that wins share when consumers trade down, a capital-light model that throws off ~$1.1B of free cash flow on ~2%-of-sales capex, a Dividend Aristocrat record stretching to 1901, and — the tell I like most — a brand-new CEO who put ~$1.75M of his own cash into the stock near the 2025 lows while the company was buying back $900M of its own shares. That is a quality business with aligned, value-aware stewards.

But the numbers say the two-decade magic has faded, and the price hasn’t caught up. Organic growth collapsed to ~0.7% in 2025 — converging to a peer-average it used to lap — and ROIC has slid from ~17% to ~13% on a string of M&A misfires: Flawless, Waterpik, and the gummy-vitamins business were all impaired and then exited, ~$840M+ of write-downs, with the vitamins franchise a near-total capital loss (bought for ~$650M, sold for $160M). Management deserves real credit for pruning the losers in 2025 — but it then paid ~$865M, roughly 7.5x sales, for Touchland, a single-product hand-sanitizer brand whose $730M trade name is the next impairment waiting to happen, so the overpay-for-growth instinct is not cured. Meanwhile the stock still trades at ~18x EV/EBITDA and ~27x adjusted earnings — a premium to Colgate (~16x), P&G (~15x) and Clorox (~11x), all of which earn higher returns on capital. You are paying a best-in-class multiple for a franchise that is now, on the evidence, merely good. Framing: a quality compounder that derated — but not enough — and now must re-prove its growth before the multiple is worth it.

Conviction: medium. Flips bullish if organic growth sustains at 3–4%+ with margin expansion (Q1 FY26’s +5% is an encouraging start, though ~2 points were an inventory tailwind) AND management pauses the over-priced M&A — that combination would re-rate the quality. Flips bearish if organic relapses toward ~1%, a fresh Waterpik/Touchland impairment lands, or another richly-priced acquisition is announced. Tag: “Iconic brands, average growth, premium price.”

1. Executive Summary

Church & Dwight is a ~$6.2B-revenue (FY2025) U.S.-centric consumer-staples company built around a portfolio of #1/#2 brands in narrow household and personal-care categories — Arm & Hammer (baking soda, value laundry detergent, cat litter), OxiClean, Trojan condoms, Batiste dry shampoo, Hero acne patches, TheraBreath mouthwash, Waterpik flossers, and the newly acquired Touchland hand sanitizer. It operates three segments — Consumer Domestic (~77% of sales), Consumer International (~18%), and the Specialty Products Division (SPD, ~5%, the largest U.S. producer of sodium bicarbonate). The model is deliberately capital-light: ~5,550 employees, capex ~2% of sales, ~$823M of net PP&E on $6.2B of revenue, and ~$1.1B of annual free cash flow.

For roughly two decades, CHD was the standout compounder in consumer staples — the fastest organic grower with the best total shareholder return, built on a differentiated “barbell” (value brands that win in downturns, premium brands that grow in good times) and a disciplined habit of acquiring #1/#2 niche brands and plugging them into its distribution. That edge has narrowed. Organic sales growth decelerated from ~4–5% in the normal years (FY2021, FY2023, FY2024) to just ~0.7% in FY2025 — roughly peer-average — and ROIC has compressed from ~16.7% (FY2020) to ~13.0% (FY2025). Adjusted EPS grew only ~2.6% in FY2025 and gross margin fell ~100bps, missing every leg of the company’s own “Evergreen Model” (≈3–4% organic, ~8% EPS, annual margin expansion).

The proximate cause of the ROIC decline is a string of M&A capital misallocations. Three of CHD’s larger deals — Waterpik (2017, ~$1.0B), Flawless (2019, ~$475M), and the gummy-vitamins/VMS business (2012, ~$650M) — were impaired and ultimately exited, totaling ~$840M+ of impairment charges across 2022/2024/2025 plus a near-total capital loss on VMS (sold for $160M at end-2025). To its credit, management spent 2025 cleaning house — divesting Spinbrush, Flawless, Waterpik showerheads, and the VMS business (collectively reducing reported FY2026 revenue ~8%) — a constructive admission. But in the same year it paid ~$865M (≈7.5x sales) for Touchland, booking a $730M trade name that now carries the same impairment risk profile as the deals that preceded it.

Financially the business remains high-quality and defensive: ~45% gross margins, ~22% EBITDA margins, strong FCF conversion, a clean investment-grade balance sheet (net debt ~$1.8B, ~1.4x EBITDA), a Dividend Aristocrat record, and a value-tier portfolio that is gaining laundry and litter share in a pressured-consumer environment. Q1 FY2026 showed a real organic reacceleration (+5%, albeit ~2 points from an inventory tailwind), with management reaffirming a 3–4% organic / 5–8% adjusted-EPS outlook and absorbing a fresh ~$25–30M oil-driven input headwind through productivity rather than price.

At ~$97.56 the stock has derated from its ~$116 2024 highs (it bottomed near $82 in late 2025) and now trades below its own historical valuation on price/book and price/sales — but at ~18x EV/EBITDA and ~27x adjusted earnings it still carries a premium to Colgate, P&G, Kimberly-Clark and Clorox despite lower returns on capital and now-comparable growth. The embedded expectation is a return to best-in-class compounding. The evidence for that is improving but not yet proven, and the valuation gives little margin of safety if it disappoints.

2. Business Overview

Church & Dwight, founded in 1846 and headquartered in Ewing, New Jersey, develops, manufactures, and markets household and personal-care consumer products plus specialty industrial chemicals. It is run by CEO Richard A. (Rick) Dierker (formerly CFO; CEO since April 2, 2025, succeeding long-tenured Matthew Farrell) and CFO Lee McChesney (since March 2025). There is no founding-family ownership; CHD is a widely held S&P 500 company with insiders owning ~1.6%.

Three segments:

• Consumer Domestic (~77% of sales, ~85% of operating income; $4,774.8M FY2025). The core U.S. household and personal-care business. Largest category is laundry detergent (Arm & Hammer value detergent, OxiClean, Xtra deep-value); other major franchises are cat litter (Arm & Hammer), condoms (Trojan, #1 U.S.), oral care (TheraBreath #1 alcohol-free mouthwash, Waterpik #1 water flosser, Arm & Hammer toothpaste, Orajel), acne (Hero/Mighty Patch, #1), dry shampoo (Batiste), hand sanitizer (Touchland, #1), women’s health (First Response), depilatories (Nair), cold care (Zicam), and hair fibers (Toppik).
• Consumer International (~18%; $1,129.4M). Power brands (Hero, TheraBreath, Touchland, Batiste, OxiClean) sold across Canada, Europe, Mexico, Australia, and exported to 100+ countries via the Global Markets Group. The fastest-growing segment (+5.4% reported FY2025) and a stated long-term priority (grow international from ~$1B to ~$2B, partly via M&A).
• Specialty Products Division (SPD, ~5%; $299.0M). The largest U.S. producer of sodium bicarbonate (made from Wyoming trona via a Tata Chemicals partnership), plus animal-nutrition supplements and specialty cleaning. The smallest, lowest-margin, most industrial segment — but a stable, vertically-integrated cash generator that also supplies CHD’s own baking-soda-based consumer products.

Power brands. After the 2025 divestiture of the vitamins business, CHD has seven “power brands” — Arm & Hammer, OxiClean, Batiste, Waterpik, TheraBreath, Hero, and Touchland — representing ~70% of net sales and profits. Six of the seven were acquired since 2001: the franchise is substantially bought, not built.

Business model and revenue quality. CHD makes money through brand-and-marketing-driven consumer products sold through mass retail (Walmart ~23% of sales, top four customers ~44%), club, drug, dollar, pet, and e-commerce channels (~21% of consumer sales online, among the highest in staples). Manufacturing is asset-light, with meaningful contract-manufacturing use and only the strategic sodium-bicarbonate vertical owned outright. The result is a high-margin, low-capital, high-FCF profile. Revenue quality is good — recurring, low-ticket, habitual consumption — but pricing power is constrained by the heavy value-tier mix (34% of consumer revenue is value brands) and the retailer concentration. R&D is modest (~2.3% of sales, in SG&A); marketing runs ~11% of sales, the true competitive investment.

Verdict: A high-quality, defensive, capital-light branded-consumer business with genuine #1/#2 positions in attractive niches and a distinctive value/premium barbell — but a U.S.-centric, retailer-concentrated, acquisition-dependent portfolio whose growth engine has recently sputtered.

3. Industry Dynamics

CHD competes in the U.S. and global household & personal care (HPC) industry — a mature, consolidated, low-growth oligopoly that rewards dominant brands with high returns on capital but offers little structural growth.

Maturity and the normalized pricing cycle. Category growth has decelerated to roughly ~2–2.5% (P&G pegs current category growth near 2% versus a 3–4% historical norm; CHD flagged category deceleration as a 2025 headwind). The 2021–2023 staples surge was inflation/price-led, with flat-to-negative volumes; that pricing tailwind is fully spent. Growth must now be volume- and innovation-led — a harder game — which is precisely why CHD’s FY2025 organic growth fell to ~0.7% and why its 2026 plan leans on new products for roughly half of organic growth.

Private label — the defining structural threat. U.S. private-label sales hit a record ~$282.8B in 2025 (21.3% dollar share, 23.9% unit share), growing ~3x faster than national brands. Penetration is near-universal. This pressure falls hardest in exactly CHD’s value categories — value laundry and cat litter — where the line between “branded value” (Arm & Hammer dollar detergent, Xtra) and store brand is thin. CHD’s barbell is a partial defense (Arm & Hammer is the branded value option, and is gaining laundry share), but the structural pressure is real and asymmetric for CHD versus premium-tilted peers.

Retailer power and channel concentration. The HPC profit pool is squeezed between commodity input suppliers upstream and a concentrated retail oligopoly downstream (Walmart, Amazon, Costco, Kroger, dollar/club), which wields private label to discipline branded pricing. CHD’s Walmart concentration (~23%) and high e-commerce mix (~21%, over-indexed to Amazon) are double-edged — growth channels that also maximize price transparency and private-label competition.

Input-cost cyclicality. CHD buys oil-derived surfactants and resins plus packaging; gross margin is geared inversely to oil/petrochemical prices. The mid-2026 Middle East/Iran conflict has pushed a fresh ~$25–30M input-cost headwind onto CHD (oil base case ~$95–100/barrel), which the company plans to absorb through productivity rather than pricing — a relative disadvantage versus premium peers given its price-sensitive value tier. CHD is, however, less tariff-exposed than import-heavy peers (largely U.S.-sourced) and less commodity-cyclical than Kimberly-Clark (no pulp exposure).

Capital-cycle read (Marathon lens). The HPC core is the favorable Marathon case: brand/scale barriers keep capital from flooding in and competing returns away on the supply side, so high returns persist because the industry is supply-disciplined. The cautionary note here is demand-side and self-inflicted — private label appropriating the value-tier profit pool, and CHD’s own capital cycle (deploying acquisition capital into adjacencies that were then impaired).

Verdict: Structurally attractive but low-ceiling — defensive, high-ROIC, recurring-consumption, supply-disciplined, but ~2% organic growth, record-and-rising private-label penetration, intensifying retailer power, and oil-input cyclicality. A good industry to own a dominant franchise in at a sensible price; CHD’s value-tier skew makes it somewhat more private-label-exposed than Colgate or P&G, but less commodity-cyclical than Kimberly-Clark.

4. Competitive Position

CHD’s moat is a portfolio of narrow, category-local franchises — intangible-asset/brand captivity plus category-specific scale, with a distinctive low-cost value-tier overlay. There is no enterprise-wide scale moat; CHD is ~1/14th of P&G and ~1/3 of Colgate/Kimberly-Clark, and survives by avoiding head-on competition and owning niches.

Naming the moat by source (Greenwald lens):

• Brand / intangibles — real, category-local. Arm & Hammer is a ~180-year-old, near-genericized trust mark in baking soda; CHD holds #1/#2 share in baking soda, value laundry, cat litter, condoms (Trojan), dry shampoo (Batiste, world’s #1), acne patches (Hero), alcohol-free mouthwash (TheraBreath), and water flossers (Waterpik). These are habitual, low-ticket, repeat-purchase categories where brand trust drives reflexive re-purchase — Greenwald’s customer-captivity test. Stable share in these niches is the moat’s proof.
• Category-specific scale — not corporate scale. CHD’s advantage is being the dominant brand with the deepest shelf and most efficient advertising within a narrow category (litter, condoms, baking soda), which a P&G-sized rival has little incentive to attack and a small entrant cannot match. This is a real but bounded barrier.
• The value-tier as a counter-cyclical moat. ~34% of consumer revenue is value brands (Arm & Hammer dollar detergent, Xtra) that capture trade-down in downturns — a differentiated cost-advantage position the premium-only peers lack, and the structural reason CHD historically outperformed in recessions. Q1 FY2026 evidence: Arm & Hammer laundry hit record share and grew consumption +4.1% (vs. ~2.7% category) with less promotion than competitors — genuine value-tier pricing power.
• Capital-light, high-ROIC model. Even at a depressed ~13% ROIC, CHD earns well above its cost of capital — a real, if narrowing, moat.

Pressure-test — the moat is narrowing on two fronts. (1) ROIC has fallen from ~16.7% (FY2020) to ~13.0% (FY2025) — the hard scorecard of a misfiring capital-allocation flywheel. (2) Impairments confirm capital destruction outside the durable core: Flawless (beauty tools), Waterpik (showerheads), and the vitamins business had no real captivity and were written down and exited. The disciplined-#1/#2-acquirer reputation is dented, and Waterpik’s remaining trade name (carrying value $644.7M, fair value only 117% of carrying) is flagged in the 10-K as at risk of further impairment.

Direct peer contrast. CHD’s ~13% ROIC sits well below Colgate and P&G (~30%+) and below Kimberly-Clark (~18.6%), roughly with Clorox (mid-teens). Its gross margin (~45%) is below Colgate (~60%) and P&G (~51%) but above Kimberly-Clark (~36%). Its FY2025 organic growth (~0.7%) trailed Clorox (+5%) and barely exceeded Colgate/P&G — the two-decade “fastest organic grower in staples” claim is no longer visible in the numbers.

Verdict: A genuine but narrowing competitive position — real brand/category/value-tier moats where CHD is #1/#2 in habitual niches, absent in the impaired adjacencies. ROIC at ~13% (down from ~17%) is the honest measure: still above cost of capital, a durable franchise, but no longer the standout compounder it was from 2005–2020.

5. Growth History and Forward Opportunities

History: a healthy multi-year record that broke in 2025. Organic sales growth (volume + price/mix, ex-acquisitions/exits/FX) ran ~+4.3% (FY2021), ~+1.4% (FY2022, the inflation-volume air pocket), ~+5.3% (FY2023), ~+4.6% (FY2024) — solidly at or above the ~3–4% Evergreen bar, with a healthy shift from price-led growth (FY2022–23 inflation pass-through) back to volume-led growth (FY2024, +3.3% volume). Then FY2025 organic collapsed to ~0.7% — volume roughly flat (+0.8%, dragged by the declining vitamins business) and price/mix slightly negative (–0.1%, as the value/laundry business faced competition and trade-down). The core U.S. business effectively stopped growing organically in 2025, even before the divestitures hit reported revenue. Adjusted EPS grew only ~2.6% and gross margin fell ~100bps — an off-year on every Evergreen leg.

Q1 FY2026: a real, if flattered, reacceleration. Organic sales rose +5% (well above the +3% outlook), volume-led (+5.3% volume, –0.3% price/mix), with adjusted gross margin +130bps to 46.4% and adjusted EPS $0.95 (+4.4%). Management was transparent that ~2 points were a year-ago inventory-comparison tailwind, so the underlying run-rate is closer to ~3% — but CHD also reported it was #1 across all of CPG in distribution points gained, a genuine forward tailwind from its innovation pipeline. Categories grew ~3% and improved through the quarter.

Forward opportunities (quality: mixed).

• Three stated long-term core targets: grow Arm & Hammer from ~$2B to ~$3B (category extensions); grow global oral care from ~$1B to ~$1.5B behind TheraBreath (toothpaste/international); grow international from ~$1B to ~$2B (partly via M&A). The international and oral-care legs are credible — real, growing, share-leading positions.
• Innovation — new products are framed as ~half of organic growth; the Q1 distribution wins support this.
• Portfolio quality — the 2025 divestitures remove chronically declining revenue (VMS, Spinbrush, Flawless, Waterpik showerheads), concentrating the company on faster-growing value and premium lines, albeit at the cost of an ~8% reported-revenue reset.
• M&A — continued premium-niche acquisitions (Touchland, Miss Mouth’s in 2026), the historical growth engine — but also the historical source of capital destruction.

The skeptical read. The forward algorithm is credible in International and oral care but the domestic core is the question mark — FY2025 organic was ~0.7%, laundry faces structural private-label/trade-down pressure, and Walmart is ~23% of sales (limited pricing power). The growth story increasingly depends on (i) internationalizing recently acquired premium brands and (ii) continued accretive M&A — i.e., bought growth layered on a low-single-digit organic core.

Verdict: Mixed-quality growth. The long-term record was high-quality; FY2025 was a genuine stall; FY2026 is a “show-me” reacceleration that has started encouragingly but leans on an inventory tailwind and on M&A-and-international rather than a re-accelerating domestic core.

6. Financial Quality

CHD’s financials are high-quality on margins, cash flow, and the balance sheet, with the central blemish being returns on capital and GAAP earnings volatility from impairments.

Margins and returns.

Gross margin is healthy (~45%) but has been flat-to-down since FY2020 (45.2%), unlike Colgate/P&G/Kimberly-Clark which re-expanded post-2022 — a tell that CHD’s value-tier mix caps pricing power. The clearest negative is the multi-year ROIC compression (15.8%→13.0%), driven by acquisition capital deployed into brands that were later impaired.

Quality-of-earnings flags.

1. GAAP EPS is distorted by impairments. Reported diluted EPS swung from $3.38 (FY2021) to $1.68 (FY2022, Flawless/Waterpik impairment) to $3.05 (FY2023) to $2.37 (FY2024, $369M VMS impairment) to $3.02 (FY2025). The cleaner figure is adjusted EPS ~$3.53 (FY2025, +2.6%). Any P/E on GAAP EPS (e.g., the headline ~32x, at the 75th percentile of CHD’s own history) materially overstates the multiple; on adjusted EPS the trailing P/E is ~27–28x.
2. Impairment recurrence is itself the signal — see Capital Allocation . ~$840M+ of brand write-downs across 2022/2024/2025 is not noise; it is the financial footprint of M&A misjudgment.
3. Negative tangible book. Goodwill + intangibles (~$6.1B) exceed total equity (~$4.0B), so tangible book is negative — typical for a serial brand-acquirer, and the reason the impairment record matters (equity is the residual after marks on acquired brands). P/B (~5.5x, but at the 24th percentile of CHD’s own history) is the meaningful measure; tangible book is not.

Cash flow — the strong point. Operating cash flow rose to $1,215M in FY2025 (a record), against ~$122M capex (~2% of sales) → ~$1,093M free cash flow (FCF/share ~$4.50). FCF conversion exceeds net income (non-cash impairments add back), the working-capital cycle is tight (~21-day cash-conversion cycle), and FCF comfortably funds the dividend (~$287M) with large surplus for buybacks and M&A. This is a genuinely cash-generative, capital-light business.

Balance sheet — clean and investment-grade. Total debt ~$2.2B (all fixed-rate senior notes, no commercial paper outstanding at year-end), cash ~$0.4–0.5B, net debt ~$1.8B, net-debt/EBITDA ~1.36x. A $2.0B revolver (to 2030) backstops liquidity; the maturity ladder is well-termed (nearest is $425M of 2027 notes). Leverage is conservative with ample capacity for the dividend and M&A.

Verdict: High-quality on cash, margins, and balance sheet; mediocre and deteriorating on returns on capital. Economics are strong in absolute terms but the multi-year ROIC slide and impairment-driven GAAP volatility are real quality blemishes that separate today’s CHD from the pristine compounder of a decade ago.

7. Capital Allocation

Capital allocation is a tale of two halves: disciplined and shareholder-friendly on dividends and buybacks; value-destructive on M&A.

Capital returns — disciplined.

• Dividend Aristocrat. CHD has paid a dividend continuously since 1901 and raised it every year for ~29 consecutive years (most recently +4.2% to $0.3075/quarter in January 2026), at a comfortable ~39% payout of GAAP EPS (~28% of FCF). A durable, well-covered, growing dividend.
• Opportunistic 2025 buyback. CHD repurchased ~$900M of stock in FY2025 — far above its usual ~$0–500M — in tranches at falling average prices ($95.71 → $92.81 → $83.59), retiring ~9.9M shares, funded entirely with cash on hand. Buying more as the price fell is exactly the discipline you want, and it coincided with the new CEO’s personal open-market purchases. ~$229M remains on the authorization.

M&A — the central negative. CHD’s franchise is substantially acquired (six of seven power brands since 2001), and the track record splits sharply:

• Winners: TheraBreath (2021, ~$556M) and Hero (2022, ~$547M) are performing and remain power brands.
• Losers (impaired and exited): Waterpik (2017, ~$1.0B), Flawless (2019, ~$475M), and the gummy-vitamins/VMS business (2012, ~$650M) were impaired across 2022/2024/2025 (~$840M+ of charges) and then exited. The VMS franchise was a near-total capital loss — bought and built for ~$650M, impaired ~$357M, then sold for $160M at end-2025. Waterpik’s remaining trade name ($644.7M) is flagged as at risk of further impairment.
• The unresolved instinct: in the same 2025 it pruned the losers, CHD paid ~$865M all-in (≈7.5x sales, including a $159M earnout and $50M of founder stock) for Touchland, a single-product hand-sanitizer brand, booking a $730M trade name with the same impairment-exposure profile as the deals that preceded it.

This is a recurring pattern of overpaying for fragile, moat-light “growth” brands outside the durable core. The 2025 housecleaning is a genuine, constructive admission — but the Touchland multiple shows the instinct has not been abandoned.

Incentives and alignment. CEO Dierker’s FY2025 comp was ~$9.8M, ~89% variable. The annual plan is gated on net sales, gross margin, adjusted EPS, cash from operations, and (in 2025) strategic initiatives — with 2026 changes that drop the soft “strategic” metric, add a three-year cumulative cash-from-operations metric, and shift the long-term mix toward more performance shares (relative TSR). The conspicuous gap: no explicit ROIC or return-on-capital metric — a real governance blind spot for a company whose value creation depends on M&A returns and whose central problem is capital destruction in acquisitions. Insider ownership is modest (~1.6%, no founding family). The standout positive is the insider buying signal: new CEO Dierker bought ~18,804 shares (~$1.75M) on the open market near the 2025 lows, and EVP Read bought 2,000 shares — rare, genuine conviction buys for a staple where insiders own little.

Verdict: Mixed. Capital returns (1901 dividend, ~29-year Aristocrat streak, opportunistic $900M buyback at falling prices, conservative leverage, CEO open-market buying) are exemplary. Capital deployment into M&A has destroyed meaningful value and remains the central risk — and the comp plan still lacks the return-on-capital gate that would discipline it.

8. Changes and Headwinds — Last Two Years

• CEO/CFO transition (2025). Rick Dierker (ex-CFO) became CEO on April 2, 2025, succeeding Matthew Farrell; Lee McChesney joined as CFO in March 2025. A largely internal, orderly transition — and the new CEO signaled alignment by buying stock.
• The 2025 portfolio housecleaning. CHD exited Spinbrush, Flawless, and Waterpik showerheads and sold the VMS/gummy-vitamins business (to Piping Rock, $160M, December 2025) — collectively reducing reported FY2026 revenue ~8% but removing chronically declining, low-margin, and impaired businesses. A quality-upgrading but top-line-shrinking move.
• The Touchland acquisition (July 2025, ~$865M). CHD’s eighth power-brand bet (now seven after VMS), a premium hand-sanitizer brand at ~7.5x sales — the key forward M&A swing factor and impairment-watch item.
• Organic-growth stall and recovery. FY2025 organic decelerated to ~0.7% (the clearest negative in the dataset); Q1 FY2026 reaccelerated to +5% (with ~2 points of inventory tailwind). Whether this is a durable inflection or a comparison-aided blip is the central near-term question.
• Margin and Evergreen miss in 2025. Gross margin fell ~100bps and adjusted EPS grew only ~2.6%, below the ~8% Evergreen target — the first clear off-year.
• Middle East/Iran oil-driven input inflation (the live headwind). A fresh ~$25–30M incremental input-cost headwind (oil-derived surfactants, resins, diesel/transport; oil base case ~$95–100/barrel), which management plans to absorb through productivity rather than price increases — protecting volume in a pressured-consumer environment but capping margin upside.
• Private-label intensification in CHD’s value categories (laundry, litter), the structural demand-side threat.
• 2026 comp-plan improvements — dropping the soft strategic-initiatives metric, adding a cash-flow metric, and shifting toward performance shares.

Verdict: The structural changes (portfolio housecleaning, CEO alignment, comp improvements) modestly strengthen the long-term setup; the cyclical and competitive developments (organic stall, oil inflation, private label) and the unresolved M&A-overpay instinct are genuine headwinds. Net: a cleaner but slower-growing company at a still-premium price.

9. Risk Analysis

Risk of catastrophic loss is low. CHD is a diversified, defensive, investment-grade, cash-generative staple. The realistic bad outcome is not a wipeout but a de-rating-plus-stalled-growth scenario — the premium multiple normalizing toward peers while organic growth and ROIC stay subdued, a 15–25% drawdown, not a zero. A fresh large impairment (Waterpik/Touchland) or an over-priced acquisition would be the most likely trigger.

10. Valuation Discussion (Embedded Expectations)

No price target or recommendation in this section — embedded-expectations and scenario framing only.

At ~$97.56, CHD’s market cap is ~$22.4B and EV ~$24.1B, against TTM EBITDA ~$1.32B, adjusted operating income ~$1.07B, adjusted EPS ~$3.53, and FCF ~$1.1B.

Reconciling the two valuation stories. On its own history (P/B at the 24th percentile, P/S at the 45th), CHD looks below-average — it has clearly derated from the premium it commanded as the standout staples compounder, falling from ~$116 (2024) to a ~$82 low (late 2025) before recovering to ~$97. But cross-sectionally, CHD still trades at a premium EV/EBITDA and adjusted P/E to every major peer — Colgate, P&G, Kimberly-Clark, and the closest comp Clorox — despite a lower ROIC (~13% vs. 30%+ at CL/PG) and now-comparable organic growth. The honest read: CHD is cheap relative to its former self but not relative to its peers, and the peer comparison is the more relevant anchor now that its growth/return premium has eroded.

Embedded expectation. At ~18x EV/EBITDA and ~27x adjusted earnings, the market is underwriting a return to best-in-class compounding: organic growth re-accelerating durably to 3–4%+, margin expansion resuming, M&A turning accretive again, and the historical quality premium being re-earned. That is a reasonable-to-optimistic expectation — Q1 FY2026 supports the start of it, but it leans on an inventory tailwind and on international/M&A rather than a re-accelerating domestic core, and it gives little margin of safety if the stall proves structural.

Scenario frame (illustrative, on ~$3.53 adjusted FY2025 base):

• Bear — organic relapses toward ~1%, a Waterpik/Touchland impairment lands, EPS grows low-single-digits, and the multiple de-rates toward the peer ~15–16x EV/EBITDA / ~22x P/E: ~15–25% downside (roughly the late-2025 lows).
• Base — organic settles at ~3%, margins expand modestly, adjusted EPS grows ~5–7% (Evergreen low end), and the multiple holds ~17–18x: roughly the current price, total return ≈ EPS growth + ~1.3% yield.
• Bull — organic sustains at 4%+ with margin expansion and disciplined M&A, EPS compounds ~8%+, and the quality premium re-rates toward ~20x EV/EBITDA: ~15–25% upside.

Verdict: Fairly-to-fully valued. Cheaper than its own history, but a premium to higher-return peers on a franchise whose growth-and-return edge has narrowed to roughly peer-average. The FCF yield (~5%) and dividend provide downside support, but there is little valuation margin of safety at $97.56.

11. Variant Perception

Consensus view. CHD is a high-quality, defensive staples compounder going through a soft patch, with a cleaned-up portfolio, a credible Evergreen model (3–4% organic, 5–8% EPS), an encouraging Q1 reacceleration, and a new aligned CEO — a “buy the quality on the dip” story that deserves its premium multiple.

The strongest bull case. The core franchises (Arm & Hammer, Trojan, litter, baking soda, Batiste, Hero, TheraBreath) are durable #1/#2 positions; the value-tier barbell is winning share in a pressured-consumer environment (record Arm & Hammer laundry share with less promotion); the company is #1 across all CPG in distribution gains; international and oral care are real growth runways; FCF is strong and the balance sheet pristine; the dividend and a falling-price buyback provide downside support; and the new CEO bought stock near the lows. In a volatile macro, a defensive, cash-generative quality compounder at a derated-from-its-own-history multiple is a reasonable hold-to-own.

The strongest bear case. The two-decade magic has faded: organic growth converged to peer-average (~0.7% in FY2025), ROIC fell from ~17% to ~13% on repeated M&A capital destruction (~$840M+ impaired; VMS a near-total loss), and the overpay instinct persists (Touchland at ~7.5x sales, $730M impairment-exposed trade name). Private label is structurally pressuring the value tier; the domestic core is barely growing; and despite all this the stock trades at a premium to higher-ROIC peers (Colgate, P&G) on EV/EBITDA and adjusted P/E. The derating from ~$116 may not be finished. The realistic bear outcome is stalled-growth-plus-multiple-normalization toward peers.

The 3–5 assumptions that matter most:

1. Is the FY2025 organic stall a one-off or structural? (Q1 FY26 +5% is encouraging but ~2 points were an inventory tailwind.)
2. Can the value-tier defend against private label, or does it cede share at the Arm & Hammer price point?
3. Does management stop overpaying for M&A — and does Touchland/Waterpik avoid impairment?
4. Does ROIC stabilize/recover, or keep grinding lower as acquired-brand capital underperforms?
5. Is the premium-to-peers multiple defensible without a clear growth/return premium?

Falsification. The bull breaks if FY2026 organic relapses below ~2% and/or another large impairment lands — proving the stall is structural and the M&A flywheel still broken. The bear breaks if CHD sustains 4%+ organic with margin expansion and a disciplined M&A pause — re-earning the quality premium.

Factor-positioning read (where consensus may be offsides). CHD loads as a textbook low-beta defensive quality staple (Consumer Staples, LowVol, Quality, Dividend Yield all positive; negative oil and cyclicals; realized beta well below 1). It has been a multi-year laggard (~+2.5%/year over three years after a stellar long-term record) and is now bouncing (6-month relative strength +17.9%). This is a quality-that-derated profile, not a crowded momentum trade — limiting downside-air-pocket risk, but also implying the stock needs a fundamental catalyst (durable organic reacceleration) to re-rate rather than mere multiple momentum. The honest variant view: the market is pricing CHD as if its compounding premium is intact, while the fundamentals say it has narrowed to peer-average — the asymmetry favors waiting for proof of reacceleration (and a better price) over paying the premium today.

12. Fact vs. Interpretation

13. Open Questions

1. Is the Q1 FY2026 organic reacceleration durable once the ~2-point inventory tailwind laps?
2. Will Waterpik be impaired again (carrying $644.7M, fair value only 117% of carrying), and how is Touchland tracking against its ~7.5x-sales price?
3. Miss Mouth’s (2026 acquisition) — price, terms, and strategic fit (not in the FY2025 10-K).
4. Exact credit ratings (not disclosed in the filings reviewed; CHD is widely considered mid-BBB/Baa).
5. Does the domestic core re-accelerate organically, or does growth increasingly depend on international and M&A?
6. Will management add a return-on-capital metric to the comp plan to discipline M&A?
7. GLP-1 and category-maturity effects on condoms (Trojan) and other mature categories.

14. What Must Be True

Bull case — what must be true (and its falsification test):

• The FY2025 organic stall was a one-off; CHD re-accelerates durably to 3–4%+ organic with the value-tier defending share against private label. Falsifier: FY2026 organic relapses below ~2% after the inventory tailwind laps.
• M&A turns accretive and disciplined — Touchland performs, Waterpik avoids further impairment, and no new over-priced deals are struck. Falsifier: a fresh large impairment or another ~7x±sales acquisition.
• ROIC stabilizes/recovers and the quality premium is re-earned, justifying the premium-to-peers multiple. Falsifier: ROIC grinds below ~13% while the multiple compresses toward peers.

Bear case — what must be true (and its falsification test):

• The compounding edge has structurally narrowed to peer-average; organic stays low-single-digit, ROIC stays ~13%, and the premium multiple normalizes toward Colgate/P&G/Clorox. Falsifier: CHD sustains 4%+ organic with margin expansion and rising ROIC.
• Private label keeps taking value-tier share and a Waterpik/Touchland impairment confirms the M&A flywheel is still broken. Falsifier: Arm & Hammer/value brands hold or gain share and the acquired brands avoid write-downs.

The single most important swing variable is the durability of organic-growth reacceleration — whether FY2026 proves a return to best-in-class compounding or a comparison-aided pause in a structural deceleration. Watch the Q2/Q3 FY2026 organic prints (ex-inventory tailwind), Waterpik/Touchland intangible tests, and any new M&A.

15. Source Appendix

Primary sources are listed in the Source Appendix below: CHD FY2025 Form 10-K (filed 2026-02-12); Q1 FY2026 earnings-call transcript and release (period ended 2026-03-31); 2026 DEF 14A (filed 2026-03-19); the trailing five-year SEC filing corpus (10-K, 10-Q, 8-K, DEF 14A, Form 3/4/5); aggregated financial and valuation data (reconciled to filings); the Factorstoday.com factor model; own-history valuation-percentile and curated news data; and peer financials (Colgate, P&G, Kimberly-Clark, Clorox) from company releases and public data.

The analysis above contains no buy/sell recommendation and no price target. The only opinion expressed in this article is in the clearly-labeled “Claude’s Take” block at the top, which is the author’s own independent view and general information only — not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Church & Dwight Co., Inc. (NYSE: CHD) — Standard Diligence Questionnaire

Supplemental to the research memo. Report date: 2026-06-14. Fact / Interpretation / Assumption labeled where material.

General

What thoughtful questions have other investors asked about this company? The recurring Q1 FY2026 call questions were the right ones: (1) How durable is the Q1 organic reacceleration once the ~2-point year-ago inventory tailwind laps? (2) How does the Middle East oil spike flow into the $25–30M input headwind, and at what point does productivity give way to pricing? (3) Is the value/premium barbell defending share against private label in laundry and litter? (4) How is Touchland tracking, and where is M&A focused now? (5) What is the go-forward organic split by segment (U.S. ~3%, International ~7%, SPD ~5%)? These map to the memo’s swing variables: organic durability, input/margin management, and the private-label and M&A risks.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Neither extreme. Margins are mid-cycle (gross ~45%, off the FY2020 ~45.2% high but above the FY2022 ~41.9% trough); volumes are recovering from a weak FY2025 (organic ~0.7%) toward the Evergreen ~3–4%. GAAP EPS is depressed by recurring impairments; adjusted EPS (~$3.53) is the cleaner cyclical read.

Driven by external environment or internal actions? Both. The 2021–23 price-led surge was external (inflation); the FY2025 stall reflected category deceleration (external) plus self-inflicted portfolio drag (declining vitamins). The current oil headwind is external; the productivity offset is internal.

How stable are revenues? Fact/Interpretation: Very stable — defensive, recurring, low-ticket consumption across laundry, litter, oral care, condoms, personal care. The value-tier barbell adds counter-cyclical resilience (trade-down benefits Arm & Hammer). Reported revenue is being temporarily shrunk ~8% by the 2025 divestitures, but the retained base is steady.

Outlook for products/services? Mature, low-single-digit-growth categories (~2–2.5%) with pockets of faster growth (oral care/TheraBreath, acne/Hero, hand sanitizer/Touchland, international).

How big is the market — growing, shrinking, domestic or international? Global HPC is a mature, ~2–4% market; CHD is ~82% U.S. with international (~18%) the fastest-growing segment and a stated doubling target ($1B→$2B).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: More, on the demand side — private label at record-and-rising share (21.3% dollar / 23.9% unit), retailer power intensifying. Supply side remains disciplined (brand/scale barriers).

How profitable is the business (ROIC, ROE)? Fact: ROIC ~13.0%, ROE ~10.8% (FY2025) — good but declining (ROIC was ~16.7% in FY2020). Above cost of capital; below best-in-class peers.

How profitable is the industry — competitors, barriers? High-return for dominant brands (P&G/Colgate ROIC ~30%+), lower for sub-scale/value-tilted players. Barriers: brand intangibles, category scale, shelf access. CHD competes by owning #1/#2 niches.

Can the business be easily understood? Yes — branded consumer products + serial niche-brand M&A + capital-light manufacturing. The complexity is the M&A track record, not the economics.

Can it be undermined by foreign low-cost labor? Interpretation: Limited — bulky, regionally distributed, brand-driven products; the bigger substitution threat is domestic private label, not offshore labor.

Do brands matter? Decisively — Arm & Hammer (~180-year trust mark), Trojan (#1 condoms), Batiste (#1 dry shampoo), Hero (#1 acne), TheraBreath (#1 alcohol-free mouthwash). Brand habit is the core moat.

Nature of competition? Brand, shelf, price/value, and innovation; private label most acute in value categories; scale giants (P&G, Unilever) where they choose to contest.

Customers’ switching costs? Low at the individual-purchase level (habit, not contracts) — typical for consumables; defended by brand trust and repeat-purchase reflex.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: The internally-built equity in legacy brands (Arm & Hammer, Trojan) is under-carried; conversely acquired goodwill/intangibles (~$6.1B) overstate asset backing (tangible book is negative).

Off-balance-sheet liabilities? None material flagged beyond the Touchland earnout ($159M, paid 1H2026) and founder-stock vesting ($50M). Leases capitalized; no material pension/environmental overhang identified.

How conservative is the accounting? Interpretation: Reasonably conservative on the core, but the repeated acquisition impairments mean purchase accounting has been optimistic at deal time (trade names later written down). Watch adjusted vs. GAAP EPS and the Waterpik/Touchland intangible tests.

How CapEx-hungry? Very light — capex ~2% of sales (~$122M FY2025), net PP&E ~13% of sales. A capital-light, high-FCF-conversion model.

Capital Allocation & Management

How much FCF, and how is it used? Fact: ~$1.1B FCF (FY2025). Priority: dividend (~$287M) → buybacks (opportunistic, $900M in FY2025 at falling prices) → bolt-on M&A. Philosophy: shareholder-friendly returns + niche-brand acquisitions.

Significant acquisitions recently? Fact: Touchland (July 2025, ~$865M all-in, ~7.5x sales); Miss Mouth’s (2026). Prior: TheraBreath (2021), Hero (2022). The M&A track record is mixed — winners (TheraBreath, Hero) and impaired losers (Waterpik, Flawless, VMS).

Buying back shares? Yes — unusually large $900M in FY2025 (opportunistic, at falling prices); typically $0–500M. Reduced share count ~4% in FY2025.

Issuing large stock to insiders? No — SBC modest (~$58M/year); share count falling on buybacks.

Compensation policy / incentives? Fact: CEO ~$9.8M (~89% variable); metrics = net sales, gross margin, adjusted EPS, cash from operations, (+TSR in LTI). 2026 added a cash-flow metric and more performance shares. Gap: no explicit ROIC/return-on-capital metric — a governance blind spot given the impairment history.

Motivations of management? Interpretation: Professional management (no founding family; ~1.6% insider ownership), but the new CEO bought ~$1.75M of stock near the lows — a genuine alignment signal.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — ordinary NYSE common stock (1099).

Dividend policy? Fact: Paid since 1901, ~29 consecutive annual increases (Dividend Aristocrat); raised 4.2% to $0.3075/quarter (Jan 2026); ~39% payout; ~1.3% yield at ~$97.56.

How profitable is the business? See ROIC ~13% / ROE ~10.8% / EBITDA margin ~22% above.

Is net income diverging from cash from operations? Fact: OCF consistently exceeds net income (FY2025 OCF $1,215M vs. GAAP NI $737M) — driven by non-cash impairment add-backs and light working-capital needs. High-quality FCF conversion.

Risks & Downside

What would cause the stock to decline? An organic-growth relapse toward ~1%; a fresh Waterpik/Touchland impairment; a new over-priced acquisition; multiple normalization toward higher-ROIC peers; or accelerating private-label share loss.

Risk of catastrophic loss? Interpretation: Low. Diversified, defensive, investment-grade, cash-generative. Realistic downside is a 15–25% de-rating/stalled-growth drawdown (toward late-2025 lows), not a wipeout.

Chance of total loss? Negligible — strong balance sheet, broad category diversification, no single existential dependency.

Recent News & Events

Has the business environment changed recently? Fact: Yes — (1) CEO/CFO transition (Dierker/McChesney, 2025); (2) major 2025 portfolio housecleaning (exited Spinbrush/Flawless/Waterpik showerheads, sold VMS/gummy vitamins) reducing FY2026 reported sales ~8%; (3) Touchland acquisition (July 2025); (4) a fresh Middle East oil-driven input headwind (~$25–30M); (5) Q1 FY2026 organic reacceleration to +5%. The curated news feed is quiet (a small Miss Mouth’s bolt-on in 2026, neutral sentiment).

Significant acquisitions? Touchland ($865M, 2025); Miss Mouth’s (2026).

Change in accounting policies? None material beyond the portfolio actions, impairment charges, and divestiture accounting.

Recent changes — markets, facilities, management? New CEO/CFO; divested manufacturing facilities with the VMS sale; international ERP upgrade (April 2026); ongoing innovation-led distribution gains (#1 across CPG).

APPENDIX B — Source Appendix

Church & Dwight Co., Inc. (NYSE: CHD) — Source Appendix

Report date: 2026-06-14. Public primary sources first; aggregated data reconciled to filings.

Primary — SEC filings (CHD, CIK 0000313927)

• FY2025 Form 10-K (filed 2026-02-12, FY ended 2025-12-31) — segments, power brands, 2025 portfolio divestitures (Spinbrush/Flawless/Waterpik showerheads exits; VMS sale to Piping Rock), Touchland acquisition, impairments, customer concentration (Walmart ~23%), debt, R&D, employees. SEC EDGAR.
• FY2021–FY2024 Form 10-Ks — multi-year history, prior impairments (Flawless/Waterpik 2022, VMS 2024). SEC EDGAR.
• Q1 FY2026 earnings call (2026-05-01, period ended 2026-03-31) — organic +5% (incl. ~2pt inventory tailwind), adj EPS $0.95 (+4.4%), adj gross margin 46.4%, $25–30M oil/Middle East input headwind absorbed via productivity, value-barbell share gains, distribution gains #1 across CPG, e-commerce ~24%, 2026 reaffirmed (3–4% organic, 5–8% adj EPS). CHD IR (investor.churchdwight.com).
• 2026 DEF 14A proxy (filed 2026-03-19) — CEO transition (Dierker), executive comp, incentive metrics (no ROIC metric), insider ownership ~1.6%, no founding family. SEC EDGAR.
• Form 3/4/5 insider filings — new CEO Dierker open-market buys ~18,804 sh (~$1.75M) May–Aug 2025 near lows; EVP Read 2,000 sh; otherwise mechanical grant/vest/exercise. SEC EDGAR.
• 8-K filings — earnings releases, dividend declarations, M&A, CEO transition. SEC EDGAR.
• Dividend / buyback disclosures — Dividend Aristocrat (paid since 1901, ~29 consecutive annual increases), raised 4.2% to $0.3075/quarter (Jan 2026); $900M FY2025 buyback (ASR + open-market at falling prices). 10-K.

Financial, valuation & factor data (aggregated, reconciled to filings)

• Multi-period financials, ratios (ROIC 16.7%→13.0%, ROE, margins), enterprise value (~$24.1B), and 10-year valuation multiples — third-party aggregators, reconciled to the 10-K.
• Own-history valuation percentiles (as of 2026-06-12): P/E ~75th (distorted by GAAP impairments — read P/B/P/S instead), P/B ~24th, P/S ~45th, composite ~48th percentile of CHD’s own ~10-yr range; price $97.56, TTM GAAP EPS $3.02.
• Factor model (Factorstoday.com) — loadings (Consumer Staples +0.60, LowVol/Quality/DividendYield +, negative oil/cyclicals, beta ~0.05–0.5), risk-adjusted track record (multi-year laggard: y3 ~+2.5%/yr, y5 ~+4%/yr; recent 6-month bounce), relative strength (RS 6m +17.9%, RS 12m −0.3%). https://www.factorstoday.com/
• News: Miss Mouth’s stain-remover acquisition (June 2026, neutral).

Secondary — industry & peers

• Private-label data: Grocery Dive / Supermarket News / eMarketer (2025–26) — record $282.8B PL sales, 21.3% dollar / 23.9% unit share, growing ~3x national brands.
• Peer financials: Clorox FY25 results (PR Newswire); Colgate, P&G, Kimberly-Clark releases and public data (EV/EBITDA, ROIC benchmarks).
• CHD investor releases (investor.churchdwight.com) — Touchland acquisition, Q2/Q4 2025 portfolio actions, VMS divestiture.

Methodology notes

• Fiscal year ends December 31; figures reconciled to the FY2025 10-K. Adjusted EPS (~$3.53 FY2025) is used for valuation; GAAP EPS ($3.02) is distorted by non-cash impairments — the GAAP P/E and the GAAP-based valuation percentile are unreliable and were down-weighted accordingly.
• Aggregated financial-data providers are third-party, not primary; every material figure was reconciled to the 10-K/10-Q. Where they disagree with a filing, the filing governs.
• Factor and valuation-percentile data are statistical/own-history context, not price targets; treated as positioning input only.